Showing 4781-4790 of 6036 results for "".
- Aurion Biotech Names Members of Medical Advisory Boardhttps://modernod.com/news/aurion-biotech-names-members-of-medical-advisory-board/2480358/Aurion Biotech announced the company’s medical advisory board, composed of the world’s most eminent ophthalmologists. The board will collaborate with the company’s executive team in clinical development, and is chaired by Edward Holland, MD, who was recently
- Stephen D. McLeod, MD, Selected as Next CEO of American Academy of Ophthalmologyhttps://modernod.com/news/stephen-d-mcleod-md-selected-as-next-ceo-of-american-academy-of-ophthalmology/2480346/The American Academy of Ophthalmology board of trustees announced the unanimous selection of Stephen D. McLeod, MD, 57, as the Academy’s next chief executive officer (CEO). Dr. McLeod currently is the Theresa M. and Wayne M. Caygill, M.D. Distinguished Professor and Chair, Department of Oph
- SyncThink Receives Second FDA Clearance for Mobile, Rapid Test for Concussionhttps://modernod.com/news/syncthink-receives-second-fda-clearance-for-first-mobile-rapid-test-for-concussion/2480327/SyncThink has received FDA clearance for its EYE-SYNC technology as an aid to concussion, or mild traumatic brain injury (mTBI) diagnosis. EYE-SYNC received breakthrough device designation from the FDA in 2019, following the initial clearance and commercialization of the technology plat
- Nidek Launches Retina Scan Duo 2 OCT/Fundus Camerahttps://modernod.com/news/nidek-launches-retina-scan-duotm-2-octfundus-camera/2480323/Nidek has announced the launch of the Retina Scan Duo 2, a combined OCT and fundus camera system. The Retina Scan Duo 2 incorporates new features designed to enhance screening and clinical efficiency, in addition to user-friendly features that were incorporated from the previous model.<
- Hoya Vision Care and Haag-Streit Partner to Combat Myopiahttps://modernod.com/news/hoya-vision-care-and-haag-streit-partner-to-combat-myopia/2480322/Hoya Vision Care announced a strategic partnership with Haag-Streit to help address the global rise of myopia in children. The global sales and marketing agreement creates a preferred partnership between Hoya Vision Care and Haag-Streit to provide eye care professionals (ECPs) with Lenstar M
- Adverum Presents Data Showing Gene Therapy Maintained Efficacy, Durability, Safety in Wet AMD Patientshttps://modernod.com/news/adverum-data-shows-gene-therapy-maintained-efficacy-durability-safety-in-wet-amd-patients/2480318/Adverum Biotechnologies announced new long-term data from the OPTIC clinical trial of ADVM-022 single, in-office intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). Safety and efficacy data f
- Ludwin Monz Stepping Down as CEO of Carl Zeiss Meditechttps://modernod.com/news/ludwin-monz-stepping-down-as-ceo-of-carl-zeiss-meditec/2480316/President and CEO of Carl Zeiss Meditec AG Ludwin Monz, PhD, announced that he will not be accepting another term in office, and will be stepping down from his postion effective December 31, 2021. The supervisory board has appointed Markus Weber, PhD, as the new President and
- Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trialhttps://modernod.com/news/outlook-therapeutics-reports-new-positive-12-month-safety-data-from-pivotal-phase-3-norse-two-trial/2480308/Outlook Therapeutics announced new 12-month safety data from the pivotal phase 3 NORSE TWO trial that further confirm the strong safety profile in this study of ONS-5010/Lytenava (bevacizumab-vikg) for treatment of wet age-related macular degeneration (AMD). In August 2021, Outlook Ther
- Graybug Vision Reports Analysis of Data from the 6-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMDhttps://modernod.com/news/graybug-vision-reports-analysis-of-data-from-the-6-month-extension-study-of-the-altissimo-phase-2b-trial-in-wet-amd/2480304/Graybug Vision provided full-data analysis from the 18-month Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary formulation of sunitinib malate injected twice-a-year intravitreally. The ALTISSIMO trial was
- Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medicalhttps://modernod.com/news/eyevensys-enters-collaboration-with-phillips-medisize-and-minnetronix-medical/2480302/Eyevensys has entered into strategic engagements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the next generation of the company’s core technology. Terms of the deal w